Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock

au.investing.com

Spyre Therapeutics CEO Cameron Turtle sold $1.43 million in stock on Aug. 3, 2026, as shares traded near a 52-week high after a 554% yearly gain. The sales, under a Rule 10b5-1 plan adopted June 20, 2025, involved 15,000 shares priced between $93.97 and $97.46. Turtle now directly owns 567,540 shares; InvestingPro analysis currently labels the stock as overvalued. Spyre recently posted positive phase 2 data for ulcerative colitis drug SPY002; Deutsche Bank and Mizuho raised targets, but Wolfe Research downgraded on valuation. Fairmount sold its entire 4.68-million-share stake.


With a significance score of 0.9, this news ranks in the top 77% of today's 33320 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: